Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

People have a remarkable ability to infer the hidden causes of things. From physical evidence, such as muddy footprints on the floor, we can figure out what happened and who did it. Here, we investigate another source of evidence: social evaluations. Social evaluations, such as praise or blame, are commonplace in everyday conversations. While such evaluations do not fully reveal what happened, they provide valuable clues. Across three experiments, we present situations where a person was praised or blamed, and participants' task is to use that information to figure out what happened. In Experiment 1, we find that people draw systematic inferences from social evaluations about situational factors, a person's actions, capabilities, and social roles. In Experiments 2 and 3, we develop computational models that generate praise and blame judgments by considering what causal role a person's action played, and what action they should have taken. Inverting these generative models of praise and blame via Bayesian inference yields accurate predictions about what inferences participants draw based on social evaluations. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Download full-text PDF

Source
http://dx.doi.org/10.1037/pspa0000445DOI Listing

Publication Analysis

Top Keywords

social evaluations
16
praise blame
12
figure happened
8
social
5
evaluations
5
inference social
4
social evaluation
4
evaluation people
4
people remarkable
4
remarkable ability
4

Similar Publications

Caregiver Burden and 30-Day Emergency Department Revisits.

JAMA Netw Open

September 2025

Centre de recherche intégrée pour un système apprenant en santé et services sociaux, Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Lévis, Québec, Canada.

Importance: Caregivers of community-dwelling older adults play a protective role in emergency department (ED) care transitions. When the demands of caregiving result in caregiver burden, ED returns can ensue.

Objective: To develop models describing whether caregiver burden is associated with ED revisits and hospital admissions up to 30 days after discharge from an initial ED visit.

View Article and Find Full Text PDF

Abtract: PURPOSE: To evaluate the correlation between corneal backscatter and visual function in patients with Fuchs endothelial corneal dystrophy (FECD).

Study Design: Prospective case series.

Methods: This study included 53 eyes from 38 patients with FECD.

View Article and Find Full Text PDF

Purpose: Living donor kidney transplantation is a critical strategy to address the growing burden of end-stage kidney disease (ESKD) in Malaysia. Whilst living donation is generally safe, concerns remain regarding long-term donor outcomes. This study aimed to evaluate renal function and morbidity changes in living kidney donors 1 year post-donation, and to identify predictors of impaired kidney function.

View Article and Find Full Text PDF

This study aimed to evaluate the antidepressant potential of Nitazoxanide (NTZ), an antiprotozoal drug with known anti-inflammatory and neuroprotective properties, in a chronic unpredictable mild stress (CUMS)-induced mice model of depression. NTZ was administered at doses of 75, 150, and 300 mg/kg, and its effects were assessed through a series of behavioral tests, including the forced swim test, tail suspension test, actophotometer test, and social interaction test. NTZ treatment at 150 and 300 mg/kg significantly improved behavioral and biochemical outcomes, relieving depressive-like symptoms and restoring neurochemical balance.

View Article and Find Full Text PDF

Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines.

View Article and Find Full Text PDF